<DOC>
	<DOCNO>NCT02738879</DOCNO>
	<brief_summary>This trial continue sitagliptin versus withdraw sitagliptin participant Type 2 diabetes mellitus ( T2DM ) inadequate glycemic control initiate titrate insulin glargine ( LANTUS® ) base treat-to-target algorithm achieve fast glucose level 72-100 mg/dL ( 4-5.6 mmol/L ) . A primary hypothesis trial 30 week , continue sitagliptin result great reduction hemoglobin A1C ( A1C ) relative withdraw sitagliptin .</brief_summary>
	<brief_title>Randomized Sitagliptin Withdrawal Study ( MK-0431-845 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Have T2DM base American Diabetes Association guideline Be one follow treatment regimen : 1 . Stable dose sitagliptin ( 100 mg/day ) metformin IR XR ( metformin ) ( ≥1500 mg/day ) either coadministered fix dose combination ( FDC ) ≥12 week A1C 7.5 % 11.0 % , inclusive . OR 2 . Stable dose metformin ( ≥1500 mg/day ) another dipeptidyl peptidase4 ( DPP4 ) inhibitor ( maximum label dose , sitagliptin , either coadministered FDC , ≥12 week A1C 7.5 % 11.0 % , inclusive . OR 3 . Stable dose sitagliptin ( 100 mg/day ) metformin ( ≥1500 mg/day ) either coadministered FDC , sulfonylurea ≥12 week OR stable dose metformin ( ≥1500 mg/day ) sulfonylurea administer FDC sitagliptin ( 100 mg/day ) A1C 7.0 % 10.0 % , inclusive . OR 4 . Stable dose metformin ( ≥1500 mg/day ) another DPP4 inhibitor ( maximum label dose ) , sitagliptin , either coadministered FDC , sulfonylurea ≥12 week OR stable dose metformin ( ≥1500 mg/day ) sulfonylurea administer FDC another DPP4 inhibitor sitagliptin A1C 7.0 % 10.0 % , inclusive OR 5 . Stable dose metformin ( ≥1500 mg/day ) sulfonylurea either coadministered FDC ≥12 week A1C 7.5 % 11.0 % , inclusive . Meet one follow category : 1 . The participant male 2 . The participant female reproductive potential 3 . The participant female reproductive potential agree avoid become pregnant receiving study drug 14 day last dose study drug practice abstinence heterosexual activity OR use ( partner use ) acceptable contraception heterosexual activity Has treat antihyperglycemic agent ( AHA ) protocolspecified agent ( i.e. , metformin , DPP4 inhibitor , sulfonylurea agent ) within prior 12 week . Has history 2 episode hypoglycemia result seizure , coma , loss consciousness , OR recurrent ( ≥3 time per week ) episodes hypoglycemia past 8 week . Has history type 1 diabetes mellitus ( T1DM ) ketoacidosis , history latent autoimmune diabetes adult ( LADA ) , assess investigator possibly T1DM LADA confirm Cpeptide &lt; 0.7 ng/mL ( &lt; 0.23 nmol/L ) , history specific type diabetes ( e.g. , genetic syndrome , secondary pancreatic diabetes , diabetes due endocrinopathies , drug chemicalinduced , postorgan transplant ) . Is assessed investigator appropriate , agree target , fast glucose 72100 mg/dL ( 4.05.6 mmol/L ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>